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Objective: High-density lipoprotein (HDL) particles are heterogeneous in structure and function and the
role of HDL subfractions in atherogenesis is not well understood. It has been suggested that small HDL
may be dysfunctional in patients with coronary artery disease (CAD). Monocytes are considered to play a
key role in atherosclerotic diseases. Circulating monocytes can be divided into three subtypes according
to their surface expression of CD14 and CD16. Our aim was to examine whether monocyte subsets are
associated with HDL subfractions in patients with atherosclerosis. Methods: We included 90 patients
with angiographically stable CAD. Monocyte subsets were deﬁned as classical monocytes (CD14þþCD16-
; CM), intermediate monocytes (CD14þþCD16þ; IM) and non-classical monocytes (CD14þCD16þþ;
NCM). HDL subfractions were measured by electrophoresis on polyacrylamide gel. Results: Serum levels
of small HDL correlated with circulating pro-inﬂammatory NCM and showed an inverse relationship to
circulating CM independently from other lipid parameters, risk factors, inﬂammatory parameters or
statin treatment regime, respectively. IM were not associated with small HDL. In particular, patients with
small HDL levels in the highest tertile showed dramatically increased levels of NCM (14.7 ± 7% vs.
10.7 ± 5% and 10.8 ± 5%; p ¼ 0.006) and a decreased proportion of CM (79.3 ± 7% vs. 83.7 ± 6% and
83.9 ± 6%; p ¼ 0.004) compared to patients in the two lower tertiles. In contrast, intermediate HDL, large
HDL and total HDL were not associated with monocyte subset distribution. Conclusion: Small HDL levels
are associated with pro-inﬂammatory NCM and inversely correlated with CM. This may suggest that
small HDL could have dysfunctional anti-inﬂammatory properties in patients with established CAD.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Despite major advances in the ﬁeld of vascular medicine, car-
diovascular diseases remain the leading cause of death in the
western world [1]. Large clinical and epidemiological studies have
consistently and extensively demonstrated a strong inverse rela-
tionship between levels of high density lipoprotein (HDL) andedicine II, Medical University
at (J. Wojta), walter.speidl@
r Ireland Ltd. This is an open accescardiovascular diseases, independently of low-density lipoprotein
levels (LDL) [2,3]. Consequently, the concept of raising HDL levels
by therapeutic means became a strong research focus. However,
contrary to expectations, increasing HDL levels pharmacologically
failed to translate to lower one's cardiovascular risk so far [4]. One
of many prominent examples was torcetrapib, an inhibitor of the
cholesterylester transfer protein (CETP). Despite a strong increase
in HDL levels, mortality and morbidity in patients receiving the
drugwas increased causing a premature termination of a total of six
studies, including the ILLUMINATE study [5]. A growing body of
evidence suggests that under certain pathological conditions, HDLs article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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functionality [6,7].
HDLs are a heterogeneous class of lipoprotein particles with
varying structure, metabolism and anti-atherogenic properties
[8,9]. Amongst HDL subgroups, small HDL fromhealthy subjects has
been shown to exert potent atheroprotective effects including
increased potential of cholesterol efﬂux, and stronger anti-
oxidative as well as anti-inﬂammatory activities [9]. However, un-
der conditions such as atherogenic dyslipidemia, these properties
were shown to be compromised [10,11]. In clinical studies, small
HDL was associated with presence and severity of atherosclerotic
disease, while large HDLwas negatively correlatedwith presence of
coronary artery disease (CAD) and severity and progression of the
disease [12e14].
Atherosclerosis is considered to be an inﬂammatory disease in
which monocytes play a key role in all stages of the disease [15].
Within the last decade, monocyte heterogeneity was acknowl-
edged to play a role in atherogenesis [16,17]. Mononuclear cells can
be distinguished into at least three subsets by their surface
expression pattern of CD14 and CD16, namely into classical
monocytes (CD14þþCD16; CM), intermediate monocytes
(CD14þþCD16þ; IM) and non-classical monocytes
(CD14þCD16þþ; NCM), the latter two being viewed as pro-
inﬂammatory cells [18e20]. The proportion of these pro-
inﬂammatory subgroups was shown to be extended in patients
with CAD, correlated with intima media thickness in healthy adults
and was associated with plaque stability in stable and unstable
patients [21e24]. Total cholesterol, LDL-cholesterol and tri-
glycerides were correlated with the pro-inﬂammatory subset NCM,
while HDL-cholesterol showed a negative association [25,26]. In
more than 900 patients with stable CAD, IM were predictive of
cardiovascular events [27].
The functional consequence of otherwise anti-atherogenic small
HDL in dyslipidemia, metabolic syndrome and atherosclerotic dis-
ease is unknown [28,29]. As inﬂammation is crucially involved in
most of these conditions, the aim of our study was to examine
whether the different HDL subfractions are associated with the
innate immune status evidenced by monocyte subset distribution.
2. Materials and methods
2.1. Subjects and study design
In this single-center, cross-sectional study, we included 90
consecutive patients undergoing elective coronary angiography
due to stable coronary artery disease between September 2009 and
April 2010. Patients gave written, informed consent for this study,
which was approved by the local ethical committee (Medical Uni-
versity of Vienna, EK Nr. 020/2008) and complies with the Decla-
ration of Helsinki. Inclusion criteria comprised male and female
patients aged >18 years with stable CAD undergoing elective cor-
onary angiography. Excluded were patients with a recent acute
coronary syndrome deﬁned as ST-elevating myocardial infarction
(STEMI), non-STEMI or unstable angina with or without percuta-
neous coronary intervention (PCI) within the last three months,
patients with heart failure, valvular disease, malignant disease,
liver, kidney or other acute and chronic inﬂammatory diseases.
Arterial hypertension was deﬁned as systolic blood pressure
140 mmHg, diastolic blood pressure 90 mmHg in at least two
measurements or the current use of antihypertensive drugs. Sub-
jects were deﬁned as being diabetic if treated for insulin or non-
insulin-dependent diabetes mellitus or having a plasma fasting
glucose 126 mg/dL in at least two measurements. Extent of cor-
onary artery disease is given as the number of epicardial coronary
arteries with a 70% stenosis. High-dose statin treatment wasdeﬁned as treatment with atorvastatin with a dosage of at least
40 mg or rosuvastatin at a dosage of at least 10 mg daily.
2.2. Blood sampling
Blood was drawn in the morning prior to elective coronary
angiography after venipuncture from an antecubital vein using a
21-gauge butterﬂy needle (0.8 mm  19 mm; Greiner Bio-One,
Kremsmünster, Austria). After the initial 3 mL of blood were dis-
carded, blood was drawn into an EDTA tube (Greiner Bio-One) for
immediate analysis by ﬂow cytometry. Furthermore, a 3.8% sodium
citrate Vacuette tube (Greiner Bio-One; nine parts of whole blood,
one part of sodium citrate 0.129 M/L), a serum separator tube
(Greiner Bio-One) and an EDTA tube (Greiner Bio-One) were
collected, immediately centrifuged (4 C; 3000RPM for 15 min) and
stored at 80 C for later analysis.
2.3. Laboratory measurements
Granulocyte colony-stimulating factor (G-CSF), macrophage
colony-stimulating factor (M-CSF) and interleukin-6 (IL-6) were
measured using a speciﬁc enzyme-linked immunosorbent assay
(ELISA; R&D Systems, Minneapolis, MN, USA), while plasma levels
of interleukin-10 (IL-10) and granulocyteemacrophage colony-
stimulating factor (GM-CSF) were quantiﬁed using a customized
multiplex assay (Luminex Assay, R&D Systems, catalog number
FCST03). For the detection of standard laboratory markers
including high-sensitive C-reactive protein (hsCRP), blood was
analyzed in the central laboratory of the General Hospital of Vienna.
2.4. Flow cytometry
Whole blood ﬂow cytometry for determination of leukocyte and
monocyte subset distribution was performed using a FACS Canto II
with the FACS Diva Software (both Becton Dickinson). The staining
and gating strategy is outlined in Fig. 1. Brieﬂy, 100 mL of EDTA-
anticoagulated whole blood was stained with saturating concen-
trations of the following ﬂuorochrome-conjugated monoclonal
antibodies (mAbs): Peridinin chlorophyll protein (PerCP)-labeled
mAb for CD45 (Beckton Dickinson, catalog number 345809), ﬂuo-
rescein isothiocyanate (FITC)-labeled mAb for CD14 (Beckton
Dickinson, catalog number 345784), allophycocyanin (APC)-H7-
labeled mAb for CD16 (Beckton Dickinson, catalog number
560195), APC-labeled mAb for CD3 (Beckton Dickinson, catalog
number 345767), CD19 (Beckton Dickinson, catalog number
345791) and CD56 (Beckton Dickinson, catalog number 341027)
and corresponding isotype controls. After incubation for 15 min in
the dark, 1.5 mL lysing solution (BD FACS lysing solution BD Bio-
sciences) was added. After an additional 15 min of incubation in
darkness, cells were washed three times by adding 1 mL PBS and
centrifugation at 820 RPM for 5 min each. Cells were then resus-
pended in 1 mL ﬁxative solution (FACS Flow, reagent-grade water
and BD Cellﬁx™) for FACS-analysis. Monocytes were identiﬁed as
CD45-positive and CD3-, CD19-and CD56-negative cells exhibiting
a speciﬁc forward and sideward scatter proﬁle. Individual mono-
cyte subsets were deﬁned according to a recently published inter-
national consensus document as “classical monocytes” (CM;
CD14þþCD16-), “intermediate monocytes” (IM; CD14þþCD16þ)
and “non-classical monocytes” (NCM; CD14þCD16þþ) [19]. Abso-
lute numbers of monocytes were calculated using leukocyte count
as determined by the central laboratory and counts of CD45þ cells
as determined by ﬂow cytometry. For all calculations relative
numbers of monocyte subsets in percentage of total monocytes
were used. The coefﬁcient of variation for relative monocyte count
was 4.9%.
Fig. 1. Gating strategy used for monocyte subset discrimination. Monocytes were deﬁned as CD45 positive cells (B) exhibiting a typical forward (FSC) and sideward scatter (SSC)
proﬁle (A). To exclude possible contamination with T-cells, B-cells and Natural Killer cells, cells that stained for CD3, CD19 and CD56 were excluded, respectively (C). Remaining
CD45þCD3/19/56 cells with a typical FSC/SSC proﬁle were considered monocytes and distinguished according to their CD14 and CD16 surface expression into classical monocytes
(CD14þþCD16), intermediate monocytes (CD14þþCD16þ) and non-classical monocytes (CD14þCD16þþ) (D).
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For all lipid measurements, only previously unthawed serum
samples were used. Levels of total cholesterol, HDL, LDL and tri-
glycerides were measured by the general laboratory of Krankenan-
stalten Dr. Dostal using enzymaticmethods. For quantiﬁcation of HDL
subfractions, the Quantimetrix HDL Lipoprint System® (Quantime-
trix Corporation, Redondo Beach, CA, USA) was used according to
manufacturer's instructions as previously described [30]. Brieﬂy,
HDL subfraction separation and quantiﬁcation with this system is
based upon high resolution polyacrylamide gel electrophoresis and
divides HDL into 10 subfractions. Subfraction 1e3 represent large
HDL particles, subset 4e7 the intermediate HDL subtype while
subsets 8e10 represent small HDL particles [31].2.6. Statistical analysis
Categorical variables are expressed as counts or percentages and
were compared by the c2 or by Fisher's exact test where appro-
priate. Continuous variables are given as mean ± standard devia-
tion. Parametric data was compared using ANOVA, while skewed
data (assessed by the KolmogoroveSmirnov test) was compared by
ANOVA after log-transformation. Correlations were calculated us-
ing Pearson's correlation coefﬁcient. Linear regressionmodels were
calculated for all three monocyte subsets, respectively. Clinical
characteristics, statin treatment or lipid parameters were added tothe models when they were associated with monocyte subsets or
small HDL levels by a p-value <0.2. In addition, BMI was added to
the model as it has been shown to modify the association between
lipid levels and monocyte subsets. A value of p < 0.05 (two-tailed)
was considered statistically signiﬁcant. All statistical analyses were
performed with the Predictive Analysis SoftWare PASW Statistics
18.0 (IBM, Armonk, NY, USA).
3. Results
3.1. Patient characteristics
Ninety patients with angiographically proven stable coronary
artery disease were enrolled in this study. Table 1 shows the clinical
characteristics. Mean age was 64.1 ± 10.0 years, 72 patients (80%)
were male and 21 (23%) were smokers. 25 (28%) had single vessel
disease, 36 (40%) had two diseased coronary arteries and 29 pa-
tients (32%) had triple vessel disease. 31% of patients were on a
high-dose statin, 52% of patients received low-dose statin treat-
ment while 17% of patients were not treated with statins.
3.2. Correlation of HDL subfractions with lipid parameters and
cardiovascular risk factors
Small HDL levels were not associated with total HDL levels but
showed signiﬁcant correlations with triglycerides, VLDL, LDL and
Table 1
Clinical characteristics of the study population.
Total n ¼ 90 Small HDL tertile 1 n ¼ 26 Small HDL tertile 2 n ¼ 27 Small HDL tertile 3 n ¼ 37 p-value
Range, mg/dL 2e20 2e8 9e12 13e20
Age (years) 64.1 ± 10.0 64 ± 10.6 67.0 ± 9.2 62.0 ± 8.2 0.11
Male gender, n (%) 72 (80) 22 (84) 21 (78) 29 (78) 0.78
Hypertension, n (%) 80 (89) 23 (89) 23 (85) 34 (92) 0.70
Diabetes Mellitus, n (%) 27 (30) 5 (19) 10 (37) 12 (32) 0.34
Current smoker, n (%) 21 (23.3) 9 (35) 6 (22) 6 (16) 0.23
CAD Extent (VD) 0.70
1VD, n (%) 25 (28) 9 (35) 6 (22) 10 (27)
2VD, n (%) 36 (40) 16 (31) 11 (41) 9 (46)
3VD, n (%) 29 (32) 9 (35) 10 (37) 10 (27)
Statin Treatment 0.89
No Statin, n (%) 15 (17) 4 (15) 6 (22) 5 (14)
Lowedose Statin, n (%) 47 (52) 13 (50) 14 (52) 20 (54)
Highedose Statin, n (%) 28 (31) 9 (35) 7 (26) 12 (32)
BMI (kg/m2) 29 ± 4.7 28.2 ± 5.2 28.8 ± 4.2 29.8 ± 4.6 0.38
HbA1c (%) 6.1 ± 0.9 6.2 ± 1.0 5.9 ± 0.9 6.2 ± 0.8 0.65
Creatinine (mg/dL) 1.1 ± 0.3 1.0 ± 0.3 1.1 ± 0.2 1.1 ± 0.3 0.51
Leukocytes (G/L) 7.1 ± 1.7 6.9 ± 1.6 7.1 ± 1.8 7.2 ± 1.8 0.90
Triglycerides (mg/dL) 153.3 ± 81.2 124.5 ± 47.3 132.2 ± 61.8 188.9 ± 98.8 <0.001
Total cholesterol (mg/dL) 164.6 ± 39 147.5 ± 40.1 156.4 ± 34.9 182.5 ± 33.9 <0.001
HDL (mg/dL) 40.1 ± 13.4 38.8 ± 13.3 43.3 ± 14.5 40.5 ± 12.7 0.47
VLDL (mg/dL) 28.6 ± 9.4 24.7 ± 7.7 25.3 ± 6.6 40.5 ± 12.7 <0.001
LDL (mg/dL) 93.3 ± 30.8 84.5 ± 32.3 86.6 ± 28.0 104.2 ± 29.0 0.016
BMI body mass index; HDL high density lipoprotein; VLDL very low density lipoprotein; LDL low density lipoprotein; CAD coronary artery disease; VD vessel disease; Statin
dose: High-dose statin treatment was deﬁned as treatment with atorvastatin with a dosage of at least 40 mg or rosuvastatin at a dosage of at least 10 mg daily.
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inversely correlated with small HDL, highly correlated with total
HDL and correlated inversely with VLDL and triglyceride levels.
Intermediate HDL correlated with large HDL but showed in addi-
tion an association with LDL and VLDL. In contrast to small HDL,
intermediate HDL did not correlate with triglycerides. Intermediate
HDL (28.8 ± 7.1 vs. 23.7 ± 5.8 mg/dL; p ¼ 0.002) and large HDL
(19.3± 11.1 vs.10.7 ± 5.7mg/dL; p¼ 0.005) was higher in females as
compared to male patients whereas small HDL showed no gender
differences (11.3 ± 3.6 vs. 11.3 ± 4.3 mg/dL; p ¼ 0.99). Large HDL
correlated inversely with weight (r ¼ 0.28; p ¼ 0.008) whereas
the presence of diabetes, fasting glucose and HbA1c was not
associated with HDL subfractions. Similarly, the presence of hy-
pertension or smoking was not associated with HDL subfractions in
our study population. HDL subfractions did also not differ in pa-
tients with high dose statin, low dose statin or without statin
treatment (data not shown). In addition, the severity of disease, i.e.
the number of diseased vessels was not associated small HDL
(p ¼ 0.22), intermediate HDL (p ¼ 0.06) nor with large HDL
(p ¼ 0.29).Table 2
Correlation of HDL subfractions and lipid parameters.
Small HDL Intermediate HDL Large HDL
R p-value R p-value R p-value
HDL 0.060 0.56 0.68 <0.0001 0.80 <0.0001
Total
cholesterol
0.39 <0.0005 0.60 <0.0001 0.24 0.023
LDL 0.30 <0.005 0.43 <0.0001 0.11 0.30
VLDL 0.42 <0.0001 0.22 0.042 ¡0.22 0.035
Triglycerides 0.36 <0.005 0.02 0.86 ¡0.37 <0.0005
Small HDL e 0.01 0.91 ¡0.26 0.014
Intermediate
HDL
0.01 0.91 e 0.63 <0.0001
Large HDL ¡0.26 0.014 0.63 <0.0001 e
HDL high density lipoprotein; LDL low density lipoprotein; VLDL very low density
lipoprotein; signiﬁcant correlations are printed bold.3.3. Monocyte subsets are associated with small HDL serum levels
Monocyte subset distribution was determined by ﬂow cytom-
etry (Fig. 1). Mean number of CM was 270.5 ± 142.7 cells/mL
(82.1 ± 6.7% of total monocytes), mean number of circulating NCM
was 39.7 ± 28.9 cells/mL (12.3 ± 5.9% of total monocytes) and mean
number of IM was 18.7 ± 15.1 cells/mL (5.6 ± 3.3% of total mono-
cytes). Serum levels of small HDL showed an inverse relationship to
the percentage of circulating CM (r¼0.33; p¼ 0.001; Fig. 2A) and
correlated signiﬁcantly with proportion of circulating pro-
inﬂammatory NCM (r ¼ 0.30; p ¼ 0.004; Fig. 2B) while there was
no association to IM (r ¼ 0.14; p ¼ 0.20; Fig. 2C). In contrast, in-
termediate HDL, large HDL and total HDL was not associated with
monocyte subset distribution (Table 3). Linear regression analysis
revealed that small HDL was associated with levels of pro-
inﬂammatory NCM and circulating CM independently from other
lipid parameters, risk factors and statin treatment regime. Incontrast, IM were only associated with total and LDL cholesterol
(Table 4). In particular, patients with small HDL levels in the highest
tertile (13e20 mg/dL) showed the lowest levels of classical
monocytes (79.3 ± 7% vs. 83.7 ± 6% and 83.9 ± 6%; p ¼ 0.004;
Fig. 3A) when compared with patients in the middle (9e12 mg/dL)
and the lowest tertile (2e8 mg/dL). Additionally, patients in the
highest tertile of small HDL exhibited the highest levels of pro-
inﬂammatory NCM (14.7 ± 7% vs. 10.7 ± 5% and 10.8 ± 5%;
p ¼ 0.006; Fig. 3B), while levels of IM were not associated with
tertiles of small HDL (5.9 ± 3% vs. 5.6 ± 3% vs. 5.3 ± 3%; p ¼ 0.54;
Fig. 3C).
3.4. Association of HDL subfractions with circulating colony
stimulating factors and inﬂammatory markers
Serum levels of small HDL correlated signiﬁcantly with plasma
levels of G-CSF (r ¼ 0.22; p ¼ 0.05) but not with plasma levels of
GM-CSF (r ¼ 0.05; p ¼ 0.66) or M-CSF (r ¼ 0.09; p ¼ 0.37). In-
termediate HDL, large HDL and total HDL were not associated with
the three colony stimulating factors, respectively (data not shown).
Serum levels of small HDL were not associated with the pro-
inﬂammatory markers hsCRP (r ¼ 0.05; p ¼ 0.64) and IL-6
Fig. 2. Correlation of small HDL serum levels and monocyte subsets. Given are scatter
dot plots analyzing the association between small HDL levels and the proportion of
classical monocytes (A), non-classical monocytes (B) and intermediate monocytes
(C). n ¼ 90.
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IL-10 was not associated with small HDL (r ¼ 0.06; p ¼ 0.62).
Furthermore, intermediate HDL, large HDL and total HDL did not
correlate with hsCRP, IL-6 and IL-10, respectively (data not shown).
In addition, neither the pro-inﬂammatory markers hsCRP (CM:
R¼ 0.11, p¼ 0.32; IM: R¼ 0.14, p ¼ 0.19; NCM: R¼ 0.04, p ¼ 0.68)
or IL-6 (CM: R ¼ 0.06, p ¼ 0.59; IM: R ¼ 0.13, p ¼ 0.24; NCM:
R ¼ 0.14, p ¼ 0.24) nor the anti-inﬂammatory marker IL-10 (CM:
R ¼ 0.01, p ¼ 0.94; IM: R ¼ 0.01, p ¼ 0.98; NCM: R ¼ 0.01,
p ¼ 0.94) were associated with circulating monocyte subsets.
4. Discussion
In the present study we are able to demonstrate that patients
with stable coronary artery disease and elevated levels of small HDL
exhibit a shift towards a pro-inﬂammatory monocyte subset dis-
tribution, indicated by elevated levels of non-classical monocytes
(CD14þCD16þþ) and a reduced proportion of classical monocytes
(CD14þþCD16). This was independent of established cardiovas-
cular risk factors, such as BMI, presence of diabetes mellitus,
smoking and plasma levels of hsCRP. Furthermore, neither serum
lipoproteins nor statin treatment had an impact on the observed
association of monocyte subsets and small HDL serum levels. Of
note, intermediate monocytes (CD14þþCD16þ) were not associ-
ated with small HDL serum levels in the unadjusted analysis.
Large epidemiological and prospective population studies have
clearly demonstrated an inverse correlation between serum HDL
cholesterol levels and coronary heart disease risk [4]. Atheropro-
tective properties of HDL include cholesterol efﬂux, anti-oxidative,
anti-inﬂammatory, cytoprotective, vasodilatatory and anti-
thrombotic activities [32,33]. Heterogeneity and varying function-
ality of HDL particles in different pathophysiological settings could
make the HDL-hypothesis more complex.
Pre-clinical studies and studies involving HDL-subsets from
healthy subjects provided evidence for potential anti-atherogenic
effects of small HDL particles [8]. Interestingly, under dyslipi-
demic conditions, HDL metabolism and subfraction distribution is
strongly altered to an increase in small HDL and a decrease of large
HDL particles [28,34,35]. This was shown both in patients with
merely elevated triglycerides but also in patients with elevated
total cholesterol [36,37]. Similarly to the above described ﬁndings,
in our study population including 90 patients with angiographic-
ally proven stable coronary artery disease, small HDL serum levels
were associated with an atherogenic lipid proﬁle, characterized by
an association with total cholesterol, LDL, VLDL as well as with
triglyceride levels. On the other hand, there was no correlation
between small HDL and total HDL levels to be found.
A great body of evidence suggests a shift towards small HDL
levels not only in dyslipidemic and obese patients but also in pa-
tients with established cardiovascular disease. In 115 patients un-
dergoing coronary angiography, the levels of large HDL were
strongly increased in patients with established coronary artery
disease [13]. In over 1000 adults followed for more than a decade,
elevated levels of both small and large HDL levels were predictive
for development of ischemic heart disease, however after adjust-
ment small HDL levels lost their predictive power [38]. A reduced
HDL particle size was further associated with presence of CAD in
women and levels of small HDL were elevated in patients with
acute ischemic stroke compared to healthy controls [39,40]. In a
carefully conducted study including 60 patients, small HDL levels
were associated with non-calciﬁed, larger and more unstable pla-
ques as evidenced by coronary computer tomography and intra-
vascular ultrasound [41]. A decreased HDL particle size was
associated with an unfavorable cardiovascular risk proﬁle and an
increased risk for future CAD [28]. In a cohort of 102 patients
Table 3
Correlation of HDL and HDL subfractions to circulating monocyte subsets.
Monocyte subsets Classical monocytes CD14þþCD16- Intermediate monocytes CD14þþCD16þ Non-classical monocytes CD14þCD16þþ
R p-value R p-value R p-value
Total HDL 0.08 0.45 0.06 0.60 0.12 0.25
Small HDL ¡0.33 0.001 0.14 0.20 0.30 0.004
Intermediate HDL 0.05 0.66 0.32 0.76 0.07 0.50
Large HDL 0.06 0.55 0.12 0.26 0.01 0.96
Signiﬁcant correlations are printed bold.
Table 4
Multivariate regression models for the association of small HDL and circulating monocyte subsets.
Classical monocytes CD14þþCD16- Intermediate monocytes CD14þþCD16þ Non-classical monocytes CD14þCD16þþ
Univariate p-value b p-value Univariate p-value b p-value Univariate p-value b p-value
Small HDL 0.001 0.33 0.006 0.20 0.21 0.08 0.004 0.27 0.02
Statin dose 0.21 0.14 0.19 0.45 0.07 0.49 0.31 0.12 0.25
Creatinine 0.36 0.11 0.35 0.19 0.18 0.12 0.07 0.23 0.05
VLDL 0.21 0.18 0.48 0.22 0.07 0.78 0.47 0.25 0.32
Age 0.37 0.09 0.50 0.98 0.23 0.09 0.23 0.21 0.08
LDL 0.02 0.19 0.56 0.05 0.80 0.01 0.11 0.23 0.45
BMI 0.84 0.04 0.71 0.73 0.02 0.84 0.67 0.06 0.58
Total cholesterol 0.02 0.10 0.77 0.18 0.86 0.01 0.06 0.60 0.08
Smoking 0.51 0.03 0.78 0.02 0.32 0.006 0.61 0.14 0.21
Hypertension 0.49 0.03 0.81 0.12 0.16 0.15 0.94 0.06 0.60
Log triglycerides 0.71 0.06 0.81 0.74 0.22 0.31 0.82 0.19 0.39
Gender 0.96 0.01 0.99 0.12 0.14 0.28 0.42 0.08 0.54
Total model R2 21% 0.040 24% 0.035 25% 0.031
HDL high density lipoprotein; Statin dose: High-dose statin treatment was deﬁned as treatment with atorvastatin with a dosage of at least 40 mg or rosuvastatin at a dosage of
at least 10 mg daily; VLDL very low density lipoprotein; LDL low density lipoprotein; BMI body mass index.
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matched controls, large and intermediate HDL was inversely
correlated with premature AMI, while small HDL was higher in
young AMI patients but statistical signiﬁcance was lost after
adjustment [30]. Patients with ACS exhibited elevated levels of
small HDL and lower levels of large HDLwhen compared to patients
with stable angina pectoris [42]. Furthermore, large HDL particles
were inversely associated with disease severity and progression in
60 male myocardial infarction survivors below the age of 45 [14]. In
contrast to the latter study, we were not able to demonstrate an
association between HDL subfractions and severity of disease in our
older study population.
Heterogeneity amongst monocytes, a cell population crucially
involved in atherogenesis, has been demonstrated more than two
decades ago by staining of the surface markers CD14 and CD16 [18].
CD16-positive monocytes were soon demonstrated to be expanded
in patients with acute and chronic inﬂammatory diseases including
atherosclerosis and these cells respondedwith a stronger activation
upon inﬂammatory stimuli [20,21,43]. Subset speciﬁc interactions
between lipoprotein metabolism and monocyte subset distribution
have been suggested by various observational and interventional
studies. A small cross-sectional study demonstrated an inverse
correlation between NCM and HDL, while a following study from
the same study group could not conﬁrm this ﬁnding, however
demonstrated a positive correlation between total cholesterol, LDL-
cholesterol and triglycerides and the proportion of NCM [25,26].
In our study, small HDL serum levels were inversely correlated
with classical monocytes and showed a positive correlation with
non-classical monocytes. In contrast to other studies, where the
correlations between total HDL or LDL with monocyte subsets were
diminished after adjustment for BMI [24,44], the associations in our
study were independent from traditional risk factors such as age,
sex, current smoking, BMI and presence of diabetes, as well as
statin treatment and lipoproteins in other models. When patientswere stratiﬁed into three tertiles according to their small HDL
levels, patients in the highest tertile showed a striking shift of
monocyte subsets to a more atherogenic and pro-inﬂammatory
distribution pattern, with an increased proportion of NCM and
fewer CM. Interestingly, monocyte subsets did not correlate with
plasma levels of the circulating inﬂammatory markers CRP, IL-6 or
IL-10, respectively. Data on the relationship between monocyte
subsets and circulating inﬂammatory markers is conﬂicting. While
in a population of patients with unstable angina, CD16-positive
monocytes were associated with hsCRP levels, another study
from the same group demonstrated no relationship with hsCRP
levels in patients with stable angina. Another study including a
heterogeneous cohort of CAD-patients demonstrated an associa-
tion of CD16-positive monocytes with TNF-a but not hsCRP or IL-6
[21e23]. Interestingly, a recently published study demonstrated an
increased IL-6 receptor expression on CM and IM in patients with
CAD as compared to a healthy control group [45]. In the same study,
monocyte subsets derived from patients showed a lower response
to stimulation with endotoxins when compared to monocytes
derived from healthy individuals. In addition, small HDL levels did
neither correlate with hsCRP or IL-6 nor with the anti-
inﬂammatory marker IL-10. Therefore one could speculate that it
is more likely that small HDL may have direct cellular effects and
not distinct systemic pro-inﬂammatory properties. The family of
colony-stimulating factors including M-CSF, G-CSF and GM-CSF
were ﬁrst characterized by their hematopoietic abilities. Today it
is accepted that many vascular cells can express and react to CSFs
and that CSFs are involved in atherogenesis via modulation of
macrophage phenotype altering their inﬂammatory potential and
cholesterol uptake abilities [46]. Interestingly, in cardiovascular
disease, only for M-CSF plasma levels a prognostic value was
described [47]. In our study, only plasma levels of G-CSF, the CSF
least characterized within atherogenesis, showed a weak, but sta-
tistically signiﬁcant association with small HDL levels.
Fig. 3. Monocyte subset distribution according to small HDL tertiles. Monocyte subset
distribution is associated with small HDL serum levels. Boxplots indicate median,
interquartile range (range from the 25th to the 75th percentile) and total range of
classical monocytes (A), non-classical monocytes (B) and intermediate monocytes (C).
*p < 0.01 for highest vs lower tertiles.
K.A. Krychtiuk et al. / Atherosclerosis 237 (2014) 589e596 595As this is a cross-sectional study, we can only analyze associa-
tions between HDL subfractions and monocyte subsets at one time
point and cannot draw any functional conclusions of these associ-
ations during atherogenesis. In addition, it has to be emphasized
that this study was performed in patients with established CAD.Therefore it is not possible to draw any conclusions for healthy
subjects. Whether small HDL has dysfunctional anti-inﬂammatory
or even pro-inﬂammatory properties in patients with established
disease or whether an increase of small HDL is merely a marker for
a pro-atherogenic and pro-inﬂammatory environment has to be
investigated in further studies.
In conclusion, we demonstrate evidence for an association be-
tween small HDL levels and an increase of the non-classical
monocyte subset population accompanied by a decrease in the
proportion of classical monocytes. Our ﬁndings demonstrate a pro-
inﬂammatory association between small HDL and innate immunity
in the setting of stable atherosclerotic disease.Conﬂict of interest
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